Kornimate/medical-research-clean huggingface dataset:
eus-guided combined therapy versus beta blocker therapy in primary prophylaxis o gov ii and igv i

Conditions: Gastric Varix; Cirrhosis; GastroIntestinal Bleeding

Summary: the eus-guided combined therapy of coilingand 2-octyl-cyanoacrylate in patients with gastric varices reduced rebleeding and need for reintervention in comparison to eus-guided coiling alone.the purpose of this study is to determine the efficacy of the primary prophylaxis of gov ii and igv i with the eus combined therapy versus beta blocker therapy in patients gov ii and igv that have never bleed.

gastric variceal bleeding is a severe condition associated with a high mortality. bleeding from varices bleeding will be defined as the occurrence of hematemesis and/or melena requiring \>2 u of blood or a decrease of 2 gm/dl of hemoglobin if no blood transfusion is given, with the confirmed endocopic visualization of gov ii and igv i. the beta blocker therapy is an effective method for the prevention of the first esophageal variceal bleeding; however, the efficacy in preventing first gastric variceal bleeding is controversial. the investigators aimed to compare the efficacy in preventing the first gastric variceal bleeding in patients with documented gov ii and igv i.

Eligibility criteria:
inclusion criteria: * above 18 years old * writeen informed consent provided. * proven gv (gov ii or igv i) on esophagogastroduodenoscopy and eus. * gastric varices with high-risk of bleeding (large diameter, high meld score, presence of portal hypertensive gastropathy) * patient preference for eus-guided therapy. exclusion criteria: * under 18 years old. * refuse to sign written informed consent. * pregnancy or nursing. * previous treatment of gastric varices. * non-cirrhotic portal hypertension * concurrent hepato-renal syndrome and/or multi-organ failure. * proven malignancy including hepatocellular carcinoma * platelet count less than 50,000/ml or international normalized rate (inr) \>2. * severe ascites that increases the distance between gastric or duodenal and gallbladder walls. * esophageal stricture. * uncontrolled coagulopathy.
cantharone for the treatment of perenial warts

Conditions: Wart, Genital

Summary: comparison of trichloroacetic acid versus cantharidine for the treatment of perenial warts.

warts are one of the most common sexually transmitted diseases. they are caused by the human papilloma virus (hpv) that causes cervical cancer. warts can grow, obstruct labor, and spread. patients presenting to the obgyn clinic with perenial warts were randomized to treatment with trichloroacetic acid (one of the many types of treatments) or to the treatment with cantharidine group. cantharidine is a vesicant extracted from beetle bugs which painlessly causes a small blister to form and cures the patient from the hpv infection causing the wart . we compared cosmesis, scar formation, pain and number of treatments (visits) as well as effectiveness in both groups. objectives 1. determine if cantharone is more effective than trichloroacetic acid (tca) for removal of warts 2. compare pain levels (pain during application) for each method 3. compare patient satisfaction for each method 4. compare scar formation and cosmesis for each method

Eligibility criteria:
inclusion criteria: * warts on the perenial area * less than 4mm across. exclusion criteria: * pregnancy * less than 18 years old * lesions larger than 4 millimeters across * unclear diagnosis * internal warts * diabetes * hiv * warts within 2 cm of mucosal areas

Keywords: warts trichloroacetic acid
corneal incisions with the intralase ifs femtosecond laser system

Conditions: Cataract

Summary: the intralase ifs femtosecond laser system can create corneal arcuate incisions for cataract surgery.


Eligibility criteria:
inclusion criteria: * at least 21 years of age * unilateral or bilateral cataract(s) for which phacoemulsification lens extraction and posterior chamber intraocular lens (iol) implantation has been planned * visual potential of 20/25 or better in each study eye following cataract removal and iol implantation * clear intraocular media other than cataract * available, willing and capable of complying with examination procedures and follow-up visits for the duration of the study * signed informed consent exclusion criteria: * previous intraocular or corneal surgery, including refractive surgery in the operative eye(s) * history of active or recurrent ophthalmic disease * abnormal topography, including evidence of keratoconus or pellucid marginal degeneration or irregular astigmatism in the operative eye(s) * white to white measurement less than 10 mm or greater than 14 mm * corneal pathology/abnormality that may interfere with the transmission of laser energy, laser light or precludes applanation * corneal pathology/abnormality that is predicted to cause visual acuity losses to a level of 20/30 (snellen) or worse during the study * subjects with diagnosed degenerative visual disorders (e.g., macular or other retinal pathology) that are predicted to cause visual acuity losses to a level of 20/30 (snellen) or worse during the study * subjects with conditions associated with increased risk of iol/capsule instability * pharmacologically dilated pupil size less than 5.5 mm or the presence of any pupil abnormalities * prior, current, or anticipated use during the course of the study of tamsulosin, silodosin or pilocarpine (e.g. flomax, flomaxtra, rapaflo) * history of any ocular or medical conditions that could affect corneal wound healing * poorly-controlled diabetes or subjects with diabetic retinopathy * concurrent use of topical or systemic medications that may impair corneal wound healing * acute, chronic, or uncontrolled systemic or ocular disease or illness that would, in the opinion of the investigator, increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, etc.) * ocular hypertension (\> 21 mm hg) * women who are pregnant, breast-feeding, or intend to become pregnant over the course of the study * known sensitivity or inappropriate responsiveness to any of the medications used in the post operative course * concurrent participation or participation in any other clinical trial during the duration of this clinical study including 30 days prior to preoperative visit

Keywords: cataract surgery femtosecond laser corneal incisions
radiofrequency ablation with gradual radiofrequency energy increment for hepatocellular carcinoma treatment

Conditions: Hepatocellular Carcinoma; Liver Cirrhosis; Chronic Liver Disease

Summary: to evaluate local tumor progression rate at 12 months after percutaneous radiofrequency ablation with gradual radiofrequency energy delivery mode with octopus electrodes in patients with hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * child-pugh class a or b * chronic hepatitis b or liver cirrhosis * contrast enhanced computed tomography (ct) or magnetic resonance imaging (mri) within 60 days of scheduled radiofrequency ablation (rfa) date * clinically diagnosed hepatocellular carcinoma (hcc), equal or less than 4 cm exclusion criteria: * number of hcc, equal or more than 3 * largest tumor size over 4 cm * child-pugh class c * presence of vascular invasion by hcc * platelet count less than 40,000 per mm3 or international normalized ratio (inr) prolongation over 50% * presence of extrahepatic metastasis

Keywords: radiofrequency ablation gradual radiofrequency energy increment cone-unit ablation
non-interventional study to evaluate long term safety, prescription management patterns of esmya in a long term setting

Conditions: Uterine Fibroids

Summary: this is a multi-centre, multinational, prospective, non-interventional study in females with a diagnosis of moderate to severe uterine fibroids, and for whom a treatment with esmya in a long term manner is planned, and in subjects who were previously exposed to upa in the long term phase iii studies.

this is a multi-centre, multinational, prospective, non-interventional study in females with a diagnosis of moderate to severe uterine fibroids, and for whom a treatment with esmya in a long term manner is planned, and in subjects who were previously exposed to upa in the long term phase iii studies. it is planned to enrol approximately 1,500 patients. consecutive, eligible, patients will be invited to enrol from approximately 100-150 european union (eu) clinical practice sites in approximately 15 countries. patients will be followed for an observation period of 60 months (5 years) from treatment start. investigators are to manage and treat patients according to their standard medical practice.

Eligibility criteria:
inclusion criteria: * adult women of reproductive age with a diagnosis of moderate to severe symptoms of uterine fibroids who are not eligible for surgery and for whom a intermittent treatment with esmya in a long term manner (at least 2 courses), is planned or subjects who were exposed to upa 5 or 10 mg during long term phase iii trials pgl09-027 (pearl iii extension, including patients (pearl extension 2)) or pgl11-006 (pearl iv), and * patient is willing and able to attend visits which are scheduled by her treating physician for the regular follow-up, provide the required medical data, and * patient has personally signed and dated the informed consent document indicating that she has been informed of all pertinent aspects of the study. exclusion criteria: * patient is prescribed esmya for pre-operative treatment * patient has a contraindication to receive esmya as per smpc * patient is using an investigational drug/therapy or has discontinued the use of an investigational drug/therapy within 30 days prior to study enrolment, * patient has hypersensitivity to the active substance of esmya or to one of its excipients, * not applicable to long term phase iii previous subjects who are not planning to receive esmya during this study: * patient is pregnant or plans to become pregnant within the next 12 months from treatment start, * patient is breastfeeding, * patient has genital bleeding of unknown aetiology or not due to uterine fibroids, * patient has been diagnosed with uterine, cervical, ovarian or breast cancer.
the clinical research of the safety and effectiveness evaluation for using echocardiography-guided liwen rf radiofrequency ablation system to treat hypertrophic obstructive cardiomyopathy

Conditions: Hypertrophic Obstructive Cardiomyopathy

Summary: objective to investigate the safety and effectiveness of echocardiography-guided radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy (hocm). percutaneous intramyocardial septal radiofrequency ablation (liwen procedure) is a safe and effective treatment approach for hypertrophic obstructive cardiomyopathy and results in sustained improvement in exercise capacity, persistent in reducing left ventricle outflow tract (lvot) gradient, and sustained improvement in cardiac function. in patients with disabling symptoms caused by hypertrophic obstructive cardiomyopathy (hocm),echocardiography-guided radiofrequency ablation could be a less invasive treatment option. percutaneous intramyocardial septal radiofrequency ablation (liwen procedure) is a new method for the diagnosis or treatment of heart disease by using a special diagnosis and treatment device to the heart target area under the guidance of image technology. the method breaks through the worldwide problem of the minimally invasive diagnosis and treatment of the myocardium on the beating heart, so as to avoid the x-ray radiation and contrast agent damage . as a new pathway of cardiac disease intervention, liwen procedure can be used in congenital heart disease, myocardial biopsies, drug injection, cell implantation and instrument implantation in addition to hypertrophic cardiomyopathy and cardiac tumors. it has important clinical value and broad application prospect. in this study, liwen rf radiofrequency ablation system was used to treat hocm , and evaluate its safety and effectiveness , in order to provide a new medical device for liwen procedure of hocm.


Eligibility criteria:
inclusion criteria: 1. subject has pressure gradient of left ventricular outflow tract (lvot) ≥50 mmhg（with systolic anterior motion）in the resting-state or after exercise stress test. 2. subject with obvious clinical symptoms. 3. subject with new york heart association (nyha) cardiac function ≥ ii grade. 4. subject with adequate drug treatment is not effective or cannot tolerate side effects of the drug. 5. subject was informed of the nature of the clinical study and agreed to participate in all the requirements of the clinical study, signed an informed consent form, and agreed to complete the following checks. exclusion criteria: 1. subject is pregnant, lactating, or planned to conceive during a clinical study. 2. subject with hypertrophic non-obstructive cardiomyopathy. 3. subject with interventricular septal thickness ≥ 30mm. 4. subject with sudden cardiac death index ≥ 10%. 5. subject combined with other heart diseases requires surgical treatment. 6. subject with heart failure(defined as resting heart failure after intensive anti-heart failure therapy, left ventricular fraction of ejecting\< 40%).

Keywords: cardiomyopathy, hypertrophic;techniques; treatment outcome
a pilot evaluation of adhesives and how they are impacted by output

Conditions: Ileostomy

Summary: the study investigates the impact real output has on the adhesion of adhesives.


Eligibility criteria:
inclusion criteria: 1. have given written informed consent 2. be at least 18 years of age and have full legal capacity 3. have had an ileostomy for more than one year 4. have intact skin on the area used in the evaluation 5. has an ileostomy with a diameter up to (≤) 35 mm 6. have a peristomal area accessible for application of patches/adhesive strips (assessed by investigating scientist) exclusion criteria: 1. currently receiving or have within the past 2 month received radio- and/or chemotherapy 2. currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet/injection) treatment. 3. are pregnant or breastfeeding 4. having dermatological problems in the peristomal- or abdominal area (assessed by investigating scientist) 5. participating in other interventional clinical investigations or have previously participated in this evaluation
connect 4 health: an intervention to improve childhood obesity outcomes

Conditions: Overweight; Obesity

Summary: health care system (hcs)-based interventions have been limited by their inattention to social and environmental barriers that impede improvement in obesity-related behaviors. additionally, current pediatric obesity care delivery relies on an outdated provider:patient paradigm which is ill-suited for a problem as prevalent as obesity. hcss often lack the organizational structure to provide longitudinal care for children with chronic illnesses, the clinicians to manage and support patients with chronic illnesses outside of clinic, and/or the health information systems that support the use of evidence-based practices at the point-of-care. thus, the research question this study is designed to address is whether a novel approach to care delivery that leverages delivery system and community resources and addresses socio-contextual factors will improve family-centered childhood obesity outcomes. the primary specific aims are to examine the extent to which the intervention, compared to the control condition, results in: 1. a smaller age-associated increase in bmi over a 12-month period. 2. improved parental and child ratings of pediatric health-related quality of life. the secondary aims are: 1. to examine parental ratings of quality and family-centeredness of pediatric obesity care and compare outcomes among participants in the intervention with the control condition 2. to assess change in weight-related behaviors and compare outcomes among participants in the intervention with the control condition 3. to assess the following process measures: * reach * extent of implementation * fidelity to protocol * parent satisfaction 4. to examine the extent to which neighborhood environments modify observed intervention effects 5. to assess the documentation of healthcare effectiveness data and information set (hedis) measures in participant medical records


Eligibility criteria:
inclusion criteria: * child is age 2.0 through 12.9 years at baseline primary care visit, * child's bmi is equal to or exceeds the 85th percentile for age and sex at baseline primary care visit, * at least 1 parent has an active email address, * at least one parent is comfortable reading and speaking in english. exclusion criteria: * children who do not have at least one parent/legal guardian who is able to follow study procedures for 1 year, * families who plan to leave hvma within the study time frame, * families for whom the primary care clinician thinks the intervention is inappropriate, e.g., emotional or cognitive difficulties, * children who have a sibling already enrolled in the study, * children with chronic conditions that substantially interfere with growth or physical activity participation.

Keywords: pediatric obesity overweight intervention
incentivizing behavior change skills to promote weight loss

Conditions: Obesity

Summary: the purpose of this study is to determine the feasibility of providing incentives to people enrolled in a weight-loss program for dietary self-monitoring and/or interim weight loss.

in this study, community outpatients will participate in an effective, 24-week, low-carbohydrate weight loss program delivered via biweekly group classes. an innovative information technology (it) solution will collate dietary self-monitoring data (input by patients via a mobile phone dietary application) and weight loss data (input by patients via remote scale). an algorithm will classify participants as achieving adequate or inadequate dietary self-monitoring and weight loss to earn intermittent rewards of varying value in real-time. participants will be notified of earning rewards via text messaging.

Eligibility criteria:
inclusion criteria: * desire to lose weight; * agree to attend visits per protocol; * access to telephone and transportation; * english speaking; * able to complete study measures; * smart phone with data and texting plan; * body mass index 30 kg/m2 or greater exclusion criteria: * pregnancy, breastfeeding, or lack of birth control if premenopausal * dementia, excessive alcohol use, or psychiatric illness * weight loss \>4.5 kg in month prior to screening * weight \> 380 lb (due to limit of cellular scale) * enrollment in other weight loss program * residing in nursing home or receiving home health care * unable to attend weight loss group at scheduled times * impaired hearing * medication other than metformin, incretin mimetics and incretin enhances for type 2 diabetes * unstable heart disease in 3 months prior to screening * furosemide 40 mg or higher (or equivalent) * chronic kidney disease * 2 or more errors on cognitive screener * blood pressure ≥160/100 mmhg

Keywords: obesity behavioral intervention diet
the effect of therapeutic touch and reiki application on anxiety and stress levels in female academicians

Conditions: Stress; Anxiety

Summary: stress and anxiety form an integral part of organizational life in universities. studies reveal that the stress experienced by academicians has increased dramatically in recent years. stress affects employee performance. in order to reduce the stress level of female academicians, methods such as non-pharmacological treatment, massage that can be applied to support scientific medicine, acupressure, hot and cold application, therapeutic touch should be used. the non-pharmacological methods that investigators will look at in our research are therapeutic touch and reiki. the improvement of the balance in the body and the reduction of negative effects such as pain, stress and anxiety with non-pharmacological touch methods are explained by gate control and endorphin theories. the universe of the research will be female academicians working at osmaniye korkut ata university. participants will be determined by the block randomization method. data; it will be collected using the introductory information form, depression, anxiety and stress level assessment form. tt and reiki application will have positive contributions as it is a non-pharmacological method, easy to apply and low cost. when the studies were examined, no other study was found in the same application as our study. therefore, in this study, it was aimed to evaluate the effect of therapeutic touch and reiki practice on anxiety and stress levels in female academicians.


Eligibility criteria:
inclusion criteria: * academicians who do not have any communication problems * do not have psychological problems exclusion criteria: * those who do not want to participate in the research

Keywords: academics therapeutic touch reiki
drug-drug interaction study of mra in patient with rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: this is an open-label, clinical pharmacology study to investigate drug-drug interaction in patients with ra.


Eligibility criteria:
inclusion criteria * patients who are diagnosed with ra according to the 1987 american college of rheumatology (acr) classification criteria * patients who contracted ra at least 6 months prior exclusion criteria * patients with class iv steinbrocker functional impairment at enrollment. * patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept and have been receiving treatment with leflunomide, within 12 weeks before initiation of treatment with the probe drug
comparison study between protopic (tacrolimus ointment) and elidel (pimecrolimus cream) in pediatric patients with mild atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: a study to compare the safety and efficacy of protopic and elidel in treating mild atopic dermatitis in pediatric patients


Eligibility criteria:
inclusion criteria: * patient has a diagnosis of atopic dermatitis rated mild using the investigator's global atopic dermatitis assessment involving a minimum of 5% of the body surface area, and the maximum of 20% of the body surface area * if female, and of childbearing potential, patient has a negative pregnancy test and agrees to practice effective birth control during the study exclusion criteria: * patient has a skin disorder other than atopic dermatitis in the areas to be treated * patient has extensive scarring or pigmented lesions in the areas to be treated that would interfere with rating of efficacy parameters * patient has clinically infected atopic dermatitis at baseline * patient is likely to require systemic corticosteroids, or the patient is likely to require intranasal or inhaled corticosteroids for an off-label indication or at higher doses than the maximum labeled dosing for the drug * patient has a known hypersensitivity to macrolides or any excipient of either study medication * patient has a chronic condition which is either not stable or not well controlled * patient is pregnant or breast feeding an infant

Keywords: mild atopic dermatitis protopic pediatric